Loading ...
Sorry, an error occurred while loading the content.

FW: NATAP: Cancer Drug Tested as HCV Therapy

Expand Messages
  • alleypat
    New HCV drug study: cancer drug Tarvacin Peregrine Pharmaceuticals this week announced it is ramping up testing of its cancer drug Tarvacin as a hepatitis C
    Message 1 of 1 , Jan 31, 2006
    • 0 Attachment
      New HCV drug study: cancer drug Tarvacin

      Peregrine Pharmaceuticals this week announced it is ramping up testing of
      its cancer drug Tarvacin as a hepatitis C treatment. The Phase I study is
      enrolling patients with hepatitis C rather than healthy subjects. Enrollment
      is several months ahead of schedule and should be completed by February; the
      release of preliminary data should begin by February 27. Tarvacin is
      Peregrine's first drug using its antiphospholipid technology. Certain viral
      diseases cause aminophospholipids, which are parts of the cell membrane, to
      become exposed. Phospholipids envelop the viruses, making them a target for
      the therapy. (AP)


      ----------

      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.